What's in Immatics Biotechnologies GmbH's pipeline?

Immatics Biotechnologies GmbH has 7 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 2 in Phase 2, 4 in Phase 1.

Which companies overlap with Immatics Biotechnologies GmbH's portfolio?

Top competitors by shared drug class: ModernaTX, Inc., SWOG Cancer Research Network, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/immatics-biotechnologies-gmbh.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Immatics Biotechnologies GmbH — Portfolio Competitive Intelligence Brief

Immatics Biotechnologies GmbH pipeline: 0 marketed, 0 filed, 1 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 2 Phase 2 4 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
IMA901	IMA901	phase 3	Personalized neoantigen vaccine	Patient-specific tumor neoantigens	Oncology

Therapeutic area mix

Oncology · 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

ModernaTX, Inc. · 1 shared drug class
SWOG Cancer Research Network · 1 shared drug class
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Immatics Biotechnologies GmbH:

Cite this brief

Drug Landscape (2026). Immatics Biotechnologies GmbH — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/immatics-biotechnologies-gmbh. Accessed 2026-05-16.